世界の創薬サービス市場 – 業界動向と2030年までの予測

創薬サービス市場の分析と規模

アメリカがん協会によると、2020年に約180万人が新たにがんと診断され、米国では推定606,520人ががんで亡くなっています。このように、疾病の増加とその世界的な負担により、創薬サービスの需要が高まっています。より優れた薬剤候補の特定のために、バイオインフォマティクス、ハイスループット、コンビナトリアルケミストリーなどの高度な技術の使用が増加しています。新興技術により、創薬は大幅に進化し、プロセスはより洗練され、正確で、時間がかかるようになりました。

Data Bridge Market Research の分析によると、2022 年に 146.8 億米ドルだった創薬サービス市場は、2023 年から 2030 年の予測期間中に 15.00% の CAGR で成長し、2030 年には 449.1 億米ドルに達すると予想されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Research がまとめた市場レポートには、詳細な専門家の分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みも含まれています。

創薬サービス市場の範囲とセグメンテーション

Market Definition

Drug discovery is the process of identifying a compound that can be used to treat and cure diseases. A drug discovery effort typically addresses a biological target that has been shown to play a role in disease development or begins with a molecule with interesting biological activities. Drug discovery has recently evolved significantly as a result of emerging technologies, allowing the process to become more refined, accurate, and time-consuming.   Drugs were discovered by identifying the active ingredient in traditional remedies or by chance, as in the case of penicillin.

Global Drug Discovery Services Market Dynamics

Drivers

• Rising demand for novel therapies for various therapeutic purposes

Drug discovery services market growth is expected to be driven by rising demand for novel medicine for chronic diseases and development in the global healthcare sector. Pharmaceutical and biopharma companies continue to outsource their research and development activities to contract research organisations (CROs), which provides R&D services and develop engagement models to maximise R&D productivity. The rising burden of chronic diseases is compelling governments and pharmaceutical companies to seek solutions and increase investment in clinical trials. As a result, the demand for drug discovery services will increase.

• Rising chronic disease burden

Chronic conditions such as diabetes, dementia, and cardiovascular disease have high socioeconomic costs and a high and rising patient illness burden. They cause seven out of every ten fatalities worldwide, accounting for more than 40 million deaths yearly. Chronic diseases, which are the leading causes of death and disability in the United States, account for the majority of healthcare costs. As a result, the global market for drug discovery services is expected to be driven by the prevalence of chronic diseases over the forecast period, resulting in an increase in R&D spending and research activities for developing novel drugs. There is a high demand for medications due to the increased prevalence of these chronic diseases which creates new economic opportunities for companies that provide drug discovery services.

Opportunities

• Increasing spending on R&D activities

The biopharmaceutical industry's increased R&D spending is driving demand for clinical trial and analytical test outsourcing. The global drug discovery services market is being propelled forward by increased research efforts on orphan pharmaceuticals and uncommon research diseases. The growing demand for biopharmaceutical treatments is propelling the biologics industry forward globally. Biopharmaceuticals alone account for approximately 20% of the pharmaceutical industry. The development of numerous novels and effective life-saving biologics treatments has increased demand. Biologics companies are encouraged to invest in developing new drugs for a wide range of common and uncommon diseases. Furthermore, patent expiration and rising demand for biologics in emerging markets propel the global drug discovery services market.

Restraints/Challenges

• High cost of drug molecules

A lack of skilled labor and a high target drug molecule failure rate will be the major impediments to the market. The drug development costs are high as millions of dollars are spent in preclinical research to identify a compound or design a drug.

This drug discovery services market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the drug discovery services market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Drug Discovery Services Market

The SARS-sudden CoV-2's emergence and spread prompted international multilateral organizations and private funders to pool their resources to support the development of an effective vaccine to combat the coronavirus and its variants. Around the world, a large number of scientists, technologists, and data managers are involved in everything from laboratory investigations to clinical trials. The COVID-19 intervention has assisted the government and healthcare sectors in understanding the importance of drug discovery in developing effective medications. As a result, many businesses have increased their R&D spending, and the government has prioritized drug discovery and development, which positively impacts the market for drug discovery services.

Countries' health systems are rapidly investing in research and development to combat the COVID-19 pandemic. Potential compounds were selected from the CHEMBL, ZINC, FDA-approved drugs, and clinical trial molecules. Worldwide, research teams are identifying drugs for the treatment of COVID-19 by screening both novel and existing drugs for their ability to alleviate symptoms and halt viral replication. As a result of the ongoing pandemic, the drug discovery services market is expected to benefit from the desire to find a cure for COVID-19.

Recent developments

• On December 3, 2021, Toxikon Corporation, a contract research company, acquired by Labcorp. Toxikon's acquisition is expected to broaden the company's product portfolio.
• On January 25, 2022, Evotec and Boehringer Ingelheim formed a target and drug development collaboration focused on iPSC-based disease modelling for ophthalmologic illnesses.

Global Drug Discovery Services Market Scope

The drug discovery services market is segmented on the basis of type, process, drug type and therapeutic area. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Medicinal Chemistry Services
• Biology Services
• Drug Metabolism and Pharmacokinetics

Process

• Target Validation
• Target Selection
• Hit-To-Lead Identification
• Candidate Validation
• Lead Optimization

 Drug Type

• Biologics
• Small Molecules

 Therapeutic Area

• Neurology
• Diabetes
• Oncology
• Respiratory Diseases
• Cardiovascular Diseases
• Others

Drug Discovery Services Market Regional Analysis/Insights

The drug discovery services market is analysed and market size insights and trends are provided by country, type, process, drug type and therapeutic area as referenced above.

The countries covered in the drug discovery services market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the drug discovery services market because of the availability of cutting-edge techniques, instruments, and facilities for drug discovery research in this region due to many qualified researchers and low-cost operations in emerging countries such as India and China.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the strong presence of well-established CROs, and rising R&D expenditure by pharmaceutical and biopharmaceutical companies.

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。下流および上流のバリュー チェーン分析、技術動向、ポーターの 5 つの力の分析、ケース スタディなどのデータ ポイントは、個々の国の市場シナリオを予測するために使用される指標の一部です。また、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されます。

競争環境と創薬サービス市場シェア分析

創薬サービス市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、創薬サービス市場に関連する会社の焦点にのみ関連しています。

医薬品発見サービス市場で活動している主要企業は次のとおりです。

• ゼネラル・エレクトリック（米国）
• ユーロフィンサイエンティフィック（米国）
• PPD Inc.（米国）
• シンジーン・インターナショナル・リミテッド（インド）
• 無錫AppTec（中国）
• Frontage Labs（米国）
• ガラパゴス NV (ベルギー)
• オーリジーン・ディスカバリー・テクノロジーズ（インド）
• ジェンスクリプト（米国）
• Domainex (英国)
• WILリサーチラボラトリーズLLC（米国）
• 上海メディシロン株式会社（中国）
• ラボコープ医薬品開発（米国）
• ジュビラントバイオシス株式会社（インド）
• エヴォテック（ドイツ）
• 上海ケムパートナー（中国）
• チャールズリバーラボラトリーズ（米国）
• メルク社（米国）
• サーモフィッシャーサイエンティフィック株式会社（米国） 

SKU-57114